inhibitor

The investigational drug itacitinib is one of several JAK inhibitors under investigation for their potential to prevent graft-versus-host disease when given before a stem cell transplant, which would be a new use for this therapy.

Blocking NRP1 with established compounds is one option, as NRP1 inhibitors -- including monoclonal antibodies -- have already been developed to treat cancer.

To address this question, the research team explored at a cellular level how immune checkpoint inhibitors interact with immune cells within arterial plaques.

"He’s right—we need to make appetite inhibitors available to anyone who wants them."

A key insight for developing this new experimental therapy was the idea of creating a molecule that would trap RUNX1 and inhibit its function -- a strategy known as a dominant-negative inhibitor in biology.